Drug intelligence / Profile preview

Calcimag

Development stage: Unknown
Lead developer: Sanifortpharma
Modality: Small Molecules
Administration: Oral

Overview

Calcimag is an oral dietary supplement developed by Sanifortpharma, specifically formulated to support bone health and maintain skeletal integrity. It contains a combination of calcium carbonate, vitamin D3, and magnesium. The supplement is designed to prevent the weakening of bones and teeth by providing essential minerals and enhancing their absorption and deposition into the bone matrix. Magnesium is included to facilitate better calcium utilization, while vitamin D3 supports intestinal calcium absorption, collectively contributing to mineral balance and a strong skeleton.

Brand names: Calcimag

Beyond the preview

Go deeper on Calcimag.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Calcimag.

Explore the full profile